---
title: "Survey Insights"
layout: survey-insights
permalink: "/survey-insights-drug-repurposing.html"
---


<style>
  .nav-3 a,
  .nav-3 .link-text {
    font-weight: 500;
    background-color: var(--roadmap_light);
    color: black;
    background-image: var(--project_paper);
  }

  .siroLogo {
    object-fit: contain;
    max-height: 150px;

  }

  .card-text p {
    font-size:12px;
  }
</style>

<div class="container siteContent">
  <h1>Drug repurposing</h1>

  <section>
    <div class="container">
      <h2 class="">MAKE A BARCHART and PIE CHART of how many orgs listed multiple drugs</h2>


      <div class="row py-5">
        <div class="col-12 col-xl-4">
          <p>
            Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
            dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
            ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
            nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
            anim id est laborum.
          </p>
        </div>
        <div class="col-12 col-xl-6">
          <canvas style="height:300px;" id="multipleDrugsPie"></canvas>
          <p class="text-end"><small>n = 40</small></p>
        </div>
      </div>

      <canvas style="width:60vw!important;" id="multipleDrugsBar"></canvas>
      <p class="text-end mb-5"><small>n = 40</small></p>

    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">Familiarity with drug repurposing prior to this survey</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="familiarityPrior"></canvas>
      <p class="text-end"><small>n = 138</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">Interest in pursuing drug repurposing prior to this survey</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="interestPrior"></canvas>
      <p class="text-end"><small>n = 138</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">Has your organization been involved in any drug repurposing efforts for your rare disease of
        interest?</h2>

      <div class="row py-5">
        <div class="col-12 col-xl-4">
          <p>
            Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
            dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
            ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
            nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
            anim id est laborum.
          </p>
        </div>
        <div class="col-12 col-xl-6">
          <canvas style="height:300px;" id="drugRepurposingPie"></canvas>
          <p class="text-end"><small>n = 138</small></p>
        </div>
      </div>

      <div id="drugRepurposingCloud" style="height: 400px;"></div>
      <p class="text-end"><small>n = 94 drugs</small></p>

    </div>
  </section>


  <section>
    <h2 class="pt-5 pb-2">Organizations repurposing Sirolimus</h2>

    <p>
      Both from anecdotal evidence from conversations, rare disease research events and our ROADMAP survey data, we can
      see that sirolimus (Rapamyacin) is a very commonly repurposed drug. This is because it has demonstrated efficacy
      in a number of medical conditions beyond its original intended use, which was as an immunosuppressive drug after
      organ transplantation. It has been found to have antiproliferative effects on certain types of cells, such as
      smooth muscle cells and cancer cells, and has been studied for its potential use in treating cancer,
      atherosclerosis, and even to prevent aging. Additionally, its relatively low toxicity and well-established safety
      profile make it an attractive candidate for repurposing.
    </p>

    <p class="pb-5">
      Through various sources, we have identified that as many as 17 rare disease nonprofit organizations are in various
      stages of repurposing it for their patient population, whether its supporting off label use, funding preclinical
      research or supporting clinical trials. Through the ROADMAP project, we spoke to 9 of these organizations and have
      their permission to share the following data:
    </p>

    <!-- START ROW 1 -->
    <div class="row">

      <!-- START LDGA -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo " src="/assets/images/sirolimus-logos/smalllogo-241x300.png" /> <br> <br>
              </div>
              <div class="col-9">
                <h4><a href="https://lgdalliance.org/" target="_blank">Lymphangiomatosis & Gorham's Disease Alliance
                    (LGDA)</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Complex Lymphatic Anomalies</p>
                <p class="pb-2 mt-0"> <i class="fa-solid fa-x" style="color: black;"></i>
                  &nbsp;
                  There are no FDA-approved drugs for CLAs.
                </p>
                <p>
                  CLAs are a group of rare diseases that are characterized by abnormal growth of lymphatic vessels that
                  may
                  involve multiple organ systems, including lung, spleen, soft tissue and bones
                </p>
                <p>
                  Sirolimus has shown efficacy in phase II clinical trials and is being used off label; It is currently
                  one of
                  the frontline agent for patients with complex lymphatic anomalies.
                </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END LDGA -->

      <!-- START PCP -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/PC project.jpeg" />
              </div>
              <div class="col-9">
                <h4><a href="https://www.pachyonychia.org/" target="_blank">Pachyonychia
                    Congenita Project</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Pachyonychia Congenita (PC)</p>
                <p class="pb-2"> <i class="fa-solid fa-x" style="color: black;"></i> &nbsp; There are no FDA-approved
                  drugs for PC.</p>
                <p>
                  PC is an ultra-rare, chronic, genetic autosomal dominant skin disorder, which causes lifelong limited
                  mobility and severe pain.
                </p>
                <p>
                  <a href="https://palvellatx.com/program-details/" target="_blank">Palvella therapeutics</a> is
                  conducting a <a href="https://clinicaltrials.gov/ct2/show/NCT05180708" target="_blank"> Phase III
                    clinical trial</a> called "VAPAUS" of QTORINâ„¢, a 3.9% topical sirolimus.
                </p>
                <p>
                  Palvella has been awarded both FDA Orphan Drug and Fast Track designation.
                </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END PCP -->

      <!-- START CDCN -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/CDCN logo.png" />
              </div>
              <div class="col-9">
                <h4><a href="https://cdcn.org/" target="_blank">Castleman Disease
                  Collaborative Network</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Castleman Disease</p>
                <p class="pb-2"> <i class="fa-solid fa-prescription-bottle-medical" style="color: black;"></i> &nbsp; CD has
                  one FDA-approved drug,
                  siltuximab (Sylvant), which is effective for about 30-50% of CD patients.</p>
    
                <p>
                  CD is a group of rare disorders that involve enlarged lymph nodes and a broad range of inflammatory
                  symptoms
                  and laboratory abnormalities. In CD, the cells of the immune system become hyperactivated, overproduce
                  cytokines and other inflammatory compounds, and fail to return to a surveillance mode.
                  </p>
                <p>
                  <a href="https://chasingmycure.com/" target="_blank">Dr. Fajgenbaum</a> discovered the potential for
                  treating CD with Sirolimus in 2014.
                  </p>
                  <p>
                    Sirolimus is currently being used off-label for patients with iMCD and UCD, and is being studied in a <a
                    href="https://clinicaltrials.gov/ct2/show/NCT03933904" target="_blank">Phase II clinical trial</a>.
                  </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END CDCN -->

    </div>
    <!-- END ROW 1 -->
    
    <br> <br>
    <!-- START ROW 2 -->
    <div class="row">

      <!-- START CURE HHT -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo"
                src="/assets/images/sirolimus-logos/Curehht-Horizontal-Logo-No-Tagline-Transparent-Back.PNG.png" />
                </div>
              <div class="col-9">
                <h4><a href="https://curehht.org/" target="_blank">Cure HHT</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Hereditary Hemorrhagic Telangiectasia (HHT)</p>
                <p class="pb-2"> <i class="fa-solid fa-x" style="color: black;"></i> &nbsp;
                  There are no FDA-approved drugs for HHT</p>
                                  <p>
                                    HHT is a genetic disorder that causes malformed blood vessels and can affect multiple organs of the
                                    body.
                                    The disorder is also sometimes referred to as Osler-Weber-Rendu (OWR).
                                    </p>
                <p>
                  Currently, sirolimus in a <a href="https://clinicaltrials.gov/ct2/show/NCT05269849"
                  target="_blank">Phase II
                  clinical trial</a> for patients with HHT that are experiencing moderate or severe epistaxis
                </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END CURE HHT -->
       
      <!-- START SKS -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/SKS-Logo-New2_6-5-19.png" />
              </div>
              <div class="col-9">
                <h4><a href="https://smithkingsmore.org/" target="_blank">Smith-Kingsmore
                  Syndrome Foundation</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Smith-Kingsmore syndrome (SKS)</p>
                <p class="pb-2"> <i class="fa-solid fa-x" style="color: black;"></i> &nbsp;
                  There are no FDA-approved drugs for ï»¿SKS</p>
                    <p>
                      SKS is a rare, neurodevelopmental genetic disorder, which impacts the digestive, endocrine, metabolic
                      and
                      nervous systems.                
                    </p>
                <p>
                  Sirolimus is currently being used off label for patients with SKS to treat intractable seizures.
                </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END SKS -->

      <!-- START RUNX1 -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/runx1_logo_wTag.png" />
              </div>
              <div class="col-9">
                <h4><a href="https://www.runx1-fpd.org/" target="_blank">RUNX1 Research
                  Program</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> RUNX1 familial platelet disorder</p>
                <p class="pb-2"> <i class="fa-solid fa-x" style="color: black;"></i> &nbsp;
                  There are no FDA-approved drugs for RUNX1.</p>
                    <p>
                      RUNX1-FPD is a hereditary blood disorder which predisposes an individual to developing blood cancer in
                      their lifetime.                    
                    </p>
                <p>
                  Preclinical data identified sirolimus as promising, currently developing a clinical trial.
                </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END RUNX1 -->
      </div>
      <!-- END ROW 2 -->
      <br> <br>

    <!-- START ROW 3 -->
    <div class="row">

      
      <!-- START LAM -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/LAM.svg" />
              </div>
              <div class="col-9">
                <h4><a href="https://www.thelamfoundation.org/" target="_blank">LAM
                  Foundation</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Lymphangioleiomyomatosis (LAM)</p>
                <p class="pb-2"> <i class="fa-solid fa-prescription-bottle-medical" style="color: black;"></i> &nbsp;
                  Sirolimus was <a
                    href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_rapamune_sirolimus_becomes_first_fda_approved_treatment_for_lymphangioleiomyomatosis_lam_a_rare_progressive_lung_disease"
                    target="_blank">FDA approved</a> for LAM in 2015.</p>
                    <p>
                      LAM is a rare lung disease that usually affects women; it's characterized by an abnormal growth of
                      smooth
                      muscle cells, especially in the lungs, lymphatic system and kidneys. Unregulated growth of these cells
                      can
                      lead to loss of lung function, accumulation of lymph rich-fluid in the chest and abdomen and growth of
                      tumors in the kidneys.
                          </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END LAM -->

      <!-- START MSU -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/MSU-Logo-web-ret-700.png" />
              </div>
              <div class="col-9">
                <h4><a href="https://understandingmyositis.org/" target="_blank">Myositis
                  Support and Understanding Association</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Idiopathic Inflammatory Myopathies (IIM)</p>
                <p class="pb-2"> <i class="fa-solid fa-x" style="color: black;"></i> &nbsp; There are no FDA-approved
                  therapies for any form of myositis.</p>
                        <p>
                          IIM, generally referred to as myositis, are a group of rare, acquired, incurable, systemic autoimmune
                          diseases. While myositis is classified as a muscle disease, it can also affect the heart, lungs, skin,
                          and GI tract, and can be associated with cancer. IIMs are thought to be caused by an overactive immune
                          system.
                                    </p>
                                    <p>
                                      A randomised, double-blind, placebo-controlled, proof-of-concept, <a
                                      href="https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30280-0/fulltext"
                                      target="_blank">Phase 2b clinical trial</a> was completed in 2020, which showed no evidence for
                                    efficacy of sirolimus for treating inclusion body myositis based on the clinical trial measures;
                                    however, the researchers found enough evidence of benefit in certain secondary outcomes to suggest
                                    conducting a phase 3 trial.
                    
                                    </p>
                                    <p>
                Some patients are using sirolimus off-label, but it is not currently integrated into treatment
                guidelines.

                                    </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END MSU -->


      <!-- START PROJECT FAVA -->
      <div class="col-12 col-lg-4">
        <div class="card shadow-4-strong h-100">
          <div class="card-body h-100">
            <div class="row">
              <div class="col-3 d-flex justify-content-center">
                <img class="img-fluid siroLogo" src="/assets/images/sirolimus-logos/FAVA-logo-final.webp" />
              </div>
              <div class="col-9">
                <h4><a href="https://www.projectfava.org/" target="_blank">Project FAVA</a></h4>
              </div>
              <div class="card-text px-lg-4">
                <p class="pt-3"><b>Rare disease: </b> Fibro-adipose vascular anomaly (FAVA)</p>
                <p class="pb-2"> <i class="fa-solid fa-prescription-bottle-medical" style="color: black;"></i> &nbsp; FDA
                  approved drug??????</p>
                        <p>
                          FAVA is a rare vascular anomaly occurring when the bodyâ€™s own tissue infiltrates a muscle, creating a
                          tumor-like mass typically found in one or more limbs.
                                    </p>
                                    <p>
                                      A randomised, double-blind, placebo-controlled, proof-of-concept, <a
                                      href="https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30280-0/fulltext"
                                      target="_blank">Phase 2b clinical trial</a> was completed in 2020, which showed no evidence for
                                    efficacy of sirolimus for treating inclusion body myositis based on the clinical trial measures;
                                    however, the researchers found enough evidence of benefit in certain secondary outcomes to suggest
                                    conducting a phase 3 trial.
                    
                                    </p>
                                    <p>
                                      Sirolimus is currently being used off-label.

                                    </p>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- END PROJECT FAVA -->
    </div>
    <!-- END ROW -->
  </section>


  <section>
    <div class="container">
      <h2 class="">Have any drug repurposing initiatives been done for your rare disease of interest without your
        organizationâ€™s involvement?</h2>

      <div class="row py-5">
        <div class="col-12 col-xl-4">
          <p>
            Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
            dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
            ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
            nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
            anim id est laborum.
          </p>
        </div>
        <div class="col-12 col-xl-6">
          <canvas style="height:300px;" id="drWithoutOrg"></canvas>
          <p class="text-end"><small>n = 136</small></p>
        </div>
      </div>

    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">Would you be interested in pursuing drug repurposing for your rare disease of interest in the future?
      </h2>
      <div class="row py-5">
        <div class="col-12 col-xl-4">
          <p>
            Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
            dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
            ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
            nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
            anim id est laborum.
          </p>
        </div>
        <div class="col-12 col-xl-6">
          <canvas style="height:300px;" id="drFutureInterest"></canvas>
          <p class="text-end"><small>n = 77</small></p>
        </div>
      </div>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">What are some reasons for why your organization has not pursued drug repurposing?</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="reasonsNoDr"></canvas>
      <p class="text-end"><small>n = 77</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">Through which process was this drug identified as promising for drug repurposing?</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="identifiedAsPromising"></canvas>
      <p class="text-end"><small>n = 38</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">What roadblocks have you encountered in the drug repurposing process?</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="roadblocksDuringDR"></canvas>
      <p class="text-end"><small>n = 38</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">What success endpoint(s) were you aiming for in the drug repurposing process?</h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="successEndpoints"></canvas>
      <p class="text-end"><small>n = 40</small></p>
    </div>
  </section>

  <section>
    <div class="container">
      <h2 class="">â€‹â€‹What additional support could improve the speed or efficiency of your rare disease drug repurposing
        work?
      </h2>
      <p>
        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
        magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
        consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
        pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est
        laborum.
      </p>
      <canvas style="width:60vw!important;" id="additionalSupport"></canvas>
      <p class="text-end"><small>n = 124</small></p>
    </div>
  </section>





</div>

<script>

  // HOW MANY LISTED MULTIPLE DRUGS (DONUT)
  var ctxMultipleDrugsPie = document.getElementById("multipleDrugsPie");
  var multipleDrugsPie = new Chart(ctxMultipleDrugsPie, {
    type: 'doughnut',
    data: {
      labels: ['1', '2', '3', '4', '5', '6', '7'],
      datasets: [{
        label: '# of responses',
        data: [21, 8, 3, 3, 2, 2, 1],
        backgroundColor: [color1, color2, color3, color4, color5, color6, color7]
      }]
    },
    options: {
      legend: {
        position: 'right',
        align: 'start'
      },
      responsive: false,
    }
  });

  // HOW MANY LISTED MULTIPLE DRUGS (BAR) 
  var ctxMultipleDrugsBar = document.getElementById("multipleDrugsBar");
  var multipleDrugsBar = new Chart(ctxMultipleDrugsBar, {
    type: 'horizontalBar',
    data: {
      labels: ['1', '2', '3', '4', '5', '6', '7'],
      datasets: [{
        label: '# of responses',
        data: [21, 8, 3, 3, 2, 2, 1],
        backgroundColor: [color3, color3, color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });

  // FAMILIARITY PRIOR TO TAKING SURVEY 
  var ctxFamiliarityPrior = document.getElementById("familiarityPrior");
  var familiarityPriorBar = new Chart(ctxFamiliarityPrior, {
    type: 'horizontalBar',
    data: {
      labels: ['Extremely familiar', 'Very familiar', 'Moderately familiar', 'Slightly familiar', 'Not familiar at all'],
      datasets: [{
        label: '# of responses',
        data: [17, 31, 48, 29, 13],
        backgroundColor: [color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });

  // INTEREST PRIOR TO TAKING SURVEY 
  var ctxInterestPrior = document.getElementById("interestPrior");
  var interestPriorBar = new Chart(ctxInterestPrior, {
    type: 'horizontalBar',
    data: {
      labels: ['Extremely interested', 'Very interested', 'Moderately interested', 'Slightly interested', 'Not interested at all'],
      datasets: [{
        label: '# of responses',
        data: [58, 40, 21, 13, 6],
        backgroundColor: [color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });


  // INVOLVED IN DR (PIE)
  var ctxDrugRepurposingPie = document.getElementById("drugRepurposingPie");
  var drugRepurposingPie = new Chart(ctxDrugRepurposingPie, {
    type: 'doughnut',
    data: {
      labels: ['Yes', 'No'],
      datasets: [{
        label: '# of responses',
        data: [58, 80],
        backgroundColor: [color3, color6]
      }]
    },
    options: {
      legend: {
        position: 'right',
        align: 'start'
      },
      responsive: false,
    }
  });

  // INVOLVED IN DR (WORD CLOUD) 
  am4core.useTheme(am4themes_animated);
  // Themes end

  var drugRepurposingCloud = am4core.create("drugRepurposingCloud", am4plugins_wordCloud.WordCloud);
  var series = drugRepurposingCloud.series.push(new am4plugins_wordCloud.WordCloudSeries());

  series.accuracy = 4;
  series.step = 15;
  series.rotationThreshold = 0.7;
  series.maxCount = 200;
  series.minWordLength = 2;
  series.labels.template.tooltipText = "{word}: {value}";
  series.fontFamily = "IBM Plex Sans";
  series.maxFontSize = am4core.percent(30);

  series.data = [
 {
   "tag": "Abemaciclib",
   "count": 1
 },
 {
   "tag": "Acetazolamide",
   "count": 1
 },
 {
   "tag": "Acetylleucine",
   "count": 1
 },
 {
   "tag": "Afatinib",
   "count": 2
 },
 {
   "tag": "Alpelisib",
   "count": 2
 },
 {
   "tag": "Baclofen",
   "count": 1
 },
 {
   "tag": "Baricitinib",
   "count": 1
 },
 {
   "tag": "Benralizumab",
   "count": 1
 },
 {
   "tag": "Bevacizumab",
   "count": 2
 },
 {
   "tag": "Bisphosphonates NOS",
   "count": 2
 },
 {
   "tag": "Bosutinib",
   "count": 1
 },
 {
   "tag": "Brigatinib",
   "count": 1
 },
 {
   "tag": "Budesonide",
   "count": 1
 },
 {
   "tag": "Cabozantinib",
   "count": 1
 },
 {
   "tag": "Cetuximab",
   "count": 1
 },
 {
   "tag": "Chemotheraphy NOS",
   "count": 1
 },
 {
   "tag": "Cilofexor",
   "count": 1
 },
 {
   "tag": "Clonidine",
   "count": 1
 },
 {
   "tag": "Cyclodextrin NOS",
   "count": 1
 },
 {
   "tag": "Dasatinib",
   "count": 1
 },
 {
   "tag": "Deferiprone",
   "count": 2
 },
 {
   "tag": "Desipramine",
   "count": 1
 },
 {
   "tag": "Divalproex",
   "count": 1
 },
 {
   "tag": "Domagrozumab",
   "count": 1
 },
 {
   "tag": "Dupilumab",
   "count": 2
 },
 {
   "tag": "Eflornithine",
   "count": 1
 },
 {
   "tag": "Erlotinib",
   "count": 1
 },
 {
   "tag": "Estradiol Valerate",
   "count": 1
 },
 {
   "tag": "Etanercept",
   "count": 1
 },
 {
   "tag": "Everolimus",
   "count": 3
 },
 {
   "tag": "Fenofibrate",
   "count": 1
 },
 {
   "tag": "Fingolimod",
   "count": 1
 },
 {
   "tag": "Gefitinib",
   "count": 1
 },
 {
   "tag": "Glycerol Phenylbutyrate",
   "count": 2
 },
 {
   "tag": "Idelalisib",
   "count": 1
 },
 {
   "tag": "Imatinib",
   "count": 1
 },
 {
   "tag": "Inverse Agonist NOS",
   "count": 1
 },
 {
   "tag": "Lamotrigine",
   "count": 1
 },
 {
   "tag": "Lirentelimab",
   "count": 1
 },
 {
   "tag": "Lithium",
   "count": 1
 },
 {
   "tag": "Lovastatin",
   "count": 1
 },
 {
   "tag": "Mavorixafor",
   "count": 1
 },
 {
   "tag": "Metformin",
   "count": 1
 },
 {
   "tag": "Miglustat",
   "count": 2
 },
 {
   "tag": "Nitisinone",
   "count": 1
 },
 {
   "tag": "Nivolumab",
   "count": 1
 },
 {
   "tag": "Norursodeoxycholic Acid",
   "count": 1
 },
 {
   "tag": "Omigapil",
   "count": 1
 },
 {
   "tag": "Oxytocin",
   "count": 1
 },
 {
   "tag": "Palbociclib",
   "count": 1
 },
 {
   "tag": "Pazopanib",
   "count": 1
 },
 {
   "tag": "Pemetrexed",
   "count": 1
 },
 {
   "tag": "Pomalidomide",
   "count": 1
 },
 {
   "tag": "Prednisone",
   "count": 1
 },
 {
   "tag": "Rituximab",
   "count": 1
 },
 {
   "tag": "Ruxolitinib",
   "count": 1
 },
 {
   "tag": "Sargramostim",
   "count": 1
 },
 {
   "tag": "Selumetinib",
   "count": 1
 },
 {
   "tag": "Semaglutide",
   "count": 1
 },
 {
   "tag": "Sirolimus",
   "count": 8
 },
 {
   "tag": "Sodium Oxybate",
   "count": 1
 },
 {
   "tag": "Sodium Phenylbutyrate",
   "count": 1
 },
 {
   "tag": "Statins NOS",
   "count": 1
 },
 {
   "tag": "Sulfasalazine",
   "count": 1
 },
 {
   "tag": "Sunitinib",
   "count": 1
 },
 {
   "tag": "Tacrolimus",
   "count": 1
 },
 {
   "tag": "Taselisib",
   "count": 1
 },
 {
   "tag": "Tauroursodeoxycholic Acid",
   "count": 1
 },
 {
   "tag": "Tazarotene",
   "count": 1
 },
 {
   "tag": "Tezepelumab",
   "count": 1
 },
 {
   "tag": "Trametinib",
   "count": 2
 },
 {
   "tag": "Ursodeoxycholic Acid",
   "count": 1
 },
 {
   "tag": "Vancomycin",
   "count": 1
 },
 {
   "tag": "Verapamil",
   "count": 1
 },
 {
   "tag": "Volixibat",
   "count": 1
 }
];
  series.dataFields.word = "tag";
  series.dataFields.value = "count";


  // DR W/O ORG INVOLVEMENT 
  var ctxDrWithoutOrg = document.getElementById("drWithoutOrg");
  var drWithoutOrg = new Chart(ctxDrWithoutOrg, {
    type: 'doughnut',
    data: {
      labels: ['Yes', 'No'],
      datasets: [{
        label: '# of responses',
        data: [58, 78],
        backgroundColor: [color3, color6]
      }]
    },
    options: {
      legend: {
        position: 'right',
        align: 'start'
      },
      responsive: false,
    }
  });

  // INTERESTED IN DR IN FUTURE
  var ctxDrWithoutOrg = document.getElementById("drFutureInterest");
  var drWithoutOrg = new Chart(ctxDrWithoutOrg, {
    type: 'doughnut',
    data: {
      labels: ['Yes', 'Maybe / Not sure', 'No'],
      datasets: [{
        label: '# of responses',
        data: [58, 17, 2],
        backgroundColor: [color3, color6]
      }]
    },
    options: {
      legend: {
        position: 'right',
        align: 'start'
      },
      responsive: false,
    }
  });

  // REASONS FOR NOT PURSUING DR 
  var ctxReasonsNoDr = document.getElementById("reasonsNoDr");
  var reasonsNoDrBar = new Chart(ctxReasonsNoDr, {
    type: 'horizontalBar',
    data: {
      labels: ['Lack of sufficient financial resources', 'Lack of understanding of the steps towards successful drug repurposing', 'Lack of staff to support project', 'Lack of pharmaceutical company support', 'Lack of drug target', 'Lack of resources to support systematic data collection', 'Lack of understanding of disease etiology', 'Lack of time/not a priority at present', 'Lack of research support', 'Lack of sufficient patient population to study', 'Lack of researcher network', 'Never heard of drug repurposing before', 'Lack of patient support', 'Regulatory roadblocks', 'Lack of physician support', 'None', 'No need - FDA approved drugs exist for our rare disease of interest', 'Other: other organizations already pursuing drug repurposing for our rare disease', 'Other: we do not support any research', 'Other: existing drugs do not match drug target'],
      datasets: [{
        label: '# of responses',
        data: [48, 35, 33, 31, 28, 28, 22, 17, 11, 9, 5, 5, 4, 4, 3, 3, 2, 3, 2, 1],
        backgroundColor: [color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });


  // HOW DRUG WAS IDENTIFIED AS PROMISING
  var ctxIdentifiedAsPromising = document.getElementById("identifiedAsPromising");
  var identifiedAsPromisingBar = new Chart(ctxIdentifiedAsPromising, {
    type: 'horizontalBar',
    data: {
      labels: ["Preclinical/Translational research", "Looking at similar diseases and what drugs are utilized or are promising for that patient population", "Analyzing patient's medical data to identify drugs that look promising based on off-label use", "High throughput drug screening being conducted", "Literature analysis / Meta-analysis", "Utilizing AI / ML to identify potential repurposed treatments", "Other: given as part of gene therapy"],
      datasets: [{
        label: '# of responses',
        data: [65, 28, 24, 21, 16, 2, 1],
        backgroundColor: [color3, color3, color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });


  // ROADBLOCKS ID'D DURING DR PROCESS
  var ctxRoadblocksDuringDR = document.getElementById("roadblocksDuringDR");
  var roadblocksDuringDRBar = new Chart(ctxRoadblocksDuringDR, {
    type: 'horizontalBar',
    data: {
      labels: ["Lack of sufficient financial resources", "Lack of pharmaceutical company support", "Lack of sufficient patient population to study", "None", "Lack of resources to support systematic data collection", "Lack of staff to support project", "Regulatory roadblocks", "Lack of patient support", "Lack of physician support", "Lack of understanding of the steps towards successful drug repurposing", "Lack of research support", "Lack of time / not a priority at present", "Lack of researcher network", "Other: drug did not prove to be effective", "Other: issues with clinical trial design", "Other: limited patient samples or limited access to patient samples", "Other: COVID-related challenges", "Other: FDA approval denied", "Other: issues with collaborations with academics"],
      datasets: [{
        label: '# of responses',
        data: [38, 24, 17, 14, 11, 9, 9, 7, 7, 7, 6, 6, 2, 5, 5, 2, 1, 1, 1],
        backgroundColor: [color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });

  // SUCCESS ENDPOINTS
  var ctxSuccessEndpoints = document.getElementById("successEndpoints");
  var successEndpointsBar = new Chart(ctxSuccessEndpoints, {
    type: 'horizontalBar',
    data: {
      labels: ['Drug to provide significant improvement in quality of life', 'Drug to provide significant reduction in symptoms', 'Drug to be freely available to patients off label with safety / efficacy data', 'Drug to receive FDA approval for your rare disease', 'Drug to increase life expectancy / decrease in mortality', 'Drug to be freely available to patients off label even without safety / efficacy data', 'Drug to provide cure of disease', 'Drug to provide prevention of relapse', 'Other: improve progression-free survival', 'Other: drug to be listed as standard of care', 'Other: success in preclinical research', 'Other: drug to slow disease progression'],
      datasets: [{
        label: '# of responses',
        data: [52, 50, 47, 40, 25, 5, 5, 2, 4, 2, 2, 1],
        backgroundColor: [color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3, color3]
      }]
    },
    options: {
      scales: {
        xAxes: [{
          ticks: {
            beginAtZero: true
          }
        }]
      },
      legend: {
        display: false
      },
      responsive: true,
    }
  });


  // WHAT ADDITIONAL SUPPORT COULD IMPROVE
  var ctxAdditionalSupport = document.getElementById("additionalSupport");
  var additionalSupportBar = new Chart(ctxAdditionalSupport, {
    type: 'horizontalBar',
    data: {
      labels: ['Collaboration with other organizations with a similar disease pathway or treatment target', 'Conducting preclinical work to show the drug is beneficial', 'Developing clinical trials', 'Developing definition of outcomes measures that are meaningful and robust', 'Developing or utilizing infrastructure and models', 'Identifying a drug target', 'Identifying the ideal drug', 'Improved patient access to drug (off-label)', 'Information on how to pursue drug repurposing', 'Understanding of the natural history of the disease', 'Other, please specify'],
      datasets: [{
        label: 'More Collaboration',
        backgroundColor: color1,
        data: [88, 70, 89, 75, 74, 68, 66, 66, 63, 68, 3],
      }, {
        label: 'More data / Information',
        backgroundColor: color2,
        data: [70, 79, 75, 90, 70, 86, 80, 66, 80, 85, 3],
      }
        , {
        label: 'More Resources',
        backgroundColor: color3,
        data: [64, 78, 83, 68, 83, 78, 78, 79, 72, 72, 3],
      }, {
        label: 'N/A',
        backgroundColor: color7,
        data: [8, 15, 8, 14, 16, 8, 15, 17, 7, 14, null],
      }],
    },
    options: {
      scales: {
        xAxes: [{
          stacked: true,
          ticks: {
            beginAtZero: true
          }
        }],
        yAxes: [{
          stacked: true // this also..
        }]
      },
      legend: {
        position: 'right',
        align: 'start'
      },
      responsive: true,

    }
  });


</script>